A multicenter clinical study of PTX3 detection of peripheral blood and Bronchoalveolar lavage fluid (BALF) for the diagnosis of invasive pulmonary aspergillosis (IPA)

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039235

Enrollment

Unknown

Registered

2020-10-22

Start date

2020-10-30

Completion date

Unknown

Last updated

2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

invasive pulmonary aspergillosis (IPA)

Interventions

Gold Standard:Host factor + Clinical symptoms, signs, imaging characteristics + Microbiological evidence (fungal culture, GM test) or histopathological evidence.

Index test:PX3

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >18 years; 2. Patients initially suspected of having pulmonary aspergillosis.

Exclusion criteria

Exclusion criteria: 1. Neutropenic patients; 2. Patients receiving empirical antifungal treatment before enrollment; 3. Unable to identify or exclude patients with pulmonary aspergillosis; 4. Refuse to sign the consent form; 5. The samples do not meet the requirements.

Design outcomes

Primary

Measure	Time frame
PTX3;	—

Secondary

Measure	Time frame
GM test;culture;	—

Countries

China

Contacts

Public ContactXin Su

General Hospital of Eastern Theater Command

suxinjs@163.com+86 13770619730

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026